Project Grant R21EY036547
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$422K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This $251,250 Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports research to characterize inflammatory cell infiltration in the meibomian glands and investigate the role of autoimmune CD4+ T cells in causing meibomian gland dysfunction (MGD), a leading cause of dry eye disease affecting millions. The award funds a collaborative research project between Baylor College of Medicine, which serves as the prime recipient, and the University of Houston College of...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $442,750 to the University of California, Davis to define a new model of evaporative dry eye disease (EDED). The research aims to: Define the clinical, topographical, and ultrastructural abnormalities of the ocular surface in AWAT2 knockout mice, which exhibit a dysfunctional tear film lipid layer similar to human EDED. Determine the impact of EDED on the corneal epithelial barrier...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to investigate whether estrogen is protective or detrimental to the health of corneal endothelial cells. The total award amount is $1,414,183.00 over the project period from Sep 30, 2024 to Apr 30, 2028. The key objectives are to: 1) Measure corneal thickness, endothelial cell density and morphology in male and female estrogen receptor knockout mice over one year, and examine endothelial...
This Project Grant award for $383,000 from the National Eye Institute (CFDA 93.867 - Vision Research) aims to identify social determinants of health (SDOH) indicators associated with disparities in the diagnosis, management, and prognosis of dry eye disease. The project will leverage electronic health record data from a single-center and multi-center (Sight Outcomes Research Collaborative) datasets to build prognostic models that account for individual and structural barriers to accessing eye...
The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
This $1,330,026 Project Grant awarded by the National Eye Institute (CFDA 93.867 - Vision Research) will support the development of two new mouse models of geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). The goal is to use these models to evaluate the potential of a novel antioxidant, deuterated docosahexaenoic acid (D-DHA), to protect the retinal pigment epithelium and prevent or treat AMD progression. The research will be conducted by the University of...
This $148,568 Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research at Emory University to investigate the role of scleral fibroblasts in refractive development and myopia. The primary objectives are to: 1) Identify characteristics of scleral fibroblasts in mouse eyes that undergo normal refractive development versus those exposed to myopic stimuli, and 2) Determine the role of retinoic acid signaling in driving...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This $670,496 Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to investigate the paradoxical role of anti-VEGF therapy in subretinal fibrosis (SRF) associated with neovascular age-related macular degeneration (NAMD). The project aims to elucidate the mechanisms by which anti-VEGF therapy at different disease stages impacts SRF, and to develop novel dual anti-angiogenesis and anti-fibrosis therapies. The...